This is a Healthcare Unfiltered EXCLUSIVE.
The ABIM Maintenance of Certification (MOC) saga continues. In the fiery aftermath of Aaron Goodman’s groundbreaking petition to dismantle the ABIM MOC, many events took place since then.
I am Joined on this exclusive episode by recurring guests, the outspoken Drs. Wes Fisher, Vincent Rajkumar, and Aaron Goodman himself. I dive deep into the shifts within the medical landscape over the past six months since the petition. The conversation unfolds with a critical analysis of medical societies’ responsiveness to the petition, exploring whether genuine change is underway or if inertia prevails. Together, we passionately discuss the crucial role of hospital and institution-wide rejection in catalyzing a domino effect for change. The episode doesn’t shy away from the legal battlefield either, delving into the multiple class-action anti-trust cases against ABIM MOC. Tensions rise throughout the conversation, but it concludes with a collective focus on the next steps to propel this movement forward.
Since the petition, I have taped about 6 other episodes focusing on ABIM-MOC, and I suggest you watch them all. As always, please subscribe and hit the like button. Don’t forget to share with others, and write a brief review. Also, check out my book: TOXIC EXPOSURE; The True Story behind the Monsanto Trial and the Search for Justice.
A must listen for all doctors affected by the ABIM-MOC.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
